Pieris Pharmaceuticals, Inc.: Platform technology company developing Anticalins (engineered lipocalin proteins) for oncology and respiratory diseases. 2H18 Phase 1 data for: 1) fully-proprietary IO program PRS-343 for HER2+ solid tumors (targeting 4-1BB) and 2) AZN-partnered PRS-060 for moderate-to-severe asthma (targeting IL4RA through inhalation). I-O partnerships w Seattle Genetics and Servier.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Immunotherapy, Oncology, Respiratory
Finance
Pre-earnings
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Address:
255 State Street
Boston, MA 02109
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Clients at Jefferies

New York, NY, United States, June 4 – June 7, 2019

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.